异基因造血干细胞移植（HSCT）是治疗各类血液或造血器官疾病的有效方法。移植物抗宿主病（GVHD）是由于免疫系统过度活跃攻击正常宿主组织所致。它可发生于肝脏、皮肤、眼黏膜表面、胃肠道及生殖器。 眼部GVHD在HSCT后发生于30-70%的患者。
适应症：Graft Vs Host Disease、Haematological Malignancy、Cancer
入组条件
纳入标准
- Patient aged 18 or above
- Underwent allogeneic HSCT in QMH in the two-year recruitment period
排除标准
- Underwent autologous HSCT
- Patient unable to attend follow-up visits
- Family Control Subjects The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。